What is GINKGO BIOWORKS HLDGS WTS's earnings per share (EPS)?

GINKGO BIOWORKS HLDGS WTS (DNABW) reported diluted earnings per share of -$5.64 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

GINKGO BIOWORKS HLDGS WTS (DNABW) Financials

DNABW

Trailing 12 months to June 30, 2026

Revenue $132.4M -37.0% YoY

Net Income $21.6M -90.6% YoY

EPS (Diluted) -$5.64 FY2025 annual

Free Cash Flow -$174.8M +36.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DNABW SEC filings page.

GINKGO BIOWORKS HLDGS WTS (DNABW) reported $132.4M in revenue over the twelve months to Jun 30, 2026, down 37.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DNABW FY2025 2026-08-30

A shrinking revenue base is paired with a faster operating-cost reset, but cash use remains driven mainly by operations.

Revenue fell 64.4% from FY2022 to FY2025, while combined SG&A and R&D fell 82.8%; the much faster cost reduction explains narrowing operating losses despite lower sales. This is cost-base compression, not growth powered by greater scale.

In FY2025, operating cash flow was -$171M versus free cash flow of -$179M. With capex at only $7.7M, the cash profile points to operating consumption rather than heavy reinvestment; the improvement from FY2024 therefore reflects better operations as well as reduced capital spending.

Debt-to-equity rose from 0.5x in FY2023 to 1.2x in FY2025, reducing the equity cushion behind reported obligations. Over the same span, the current ratio fell from 6.1x to 4.9x, indicating liquidity remains positive but has less excess than before; the balance-sheet shift is more consequential than either ratio viewed alone.

Financial Health Signals

Financial health score not available

GINKGO BIOWORKS HLDGS WTS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

GINKGO BIOWORKS HLDGS WTS passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

GINKGO BIOWORKS HLDGS WTS reported a net loss of $313K while operations used $171.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.2M

YoY-48.5%

QoQ+3.5%

5Y CAGR-14.3%

GINKGO BIOWORKS HLDGS WTS generated $20.2M in revenue in Q2 2026. This represents a decrease of 48.5% from the same quarter a year earlier. Against the prior quarter it is up 3.5%.

EBITDA

-$46.2M

YoY-7.7%

QoQ+21.1%

GINKGO BIOWORKS HLDGS WTS's EBITDA was -$46.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.7% from the same quarter a year earlier. Against the prior quarter it is up 21.1%.

Net Income

-$46.7M

YoY+22.5%

QoQ+43.4%

GINKGO BIOWORKS HLDGS WTS reported -$46.7M in net income in Q2 2026. This represents an increase of 22.5% from the same quarter a year earlier. Against the prior quarter it is up 43.4%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$46.9M

YoY-16.4%

QoQ+3.6%

GINKGO BIOWORKS HLDGS WTS recorded an outflow of $46.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 16.4% from the same quarter a year earlier. Against the prior quarter it is up 3.6%.

Cash & Debt

$84.5M

YoY-58.5%

QoQ-41.2%

5Y CAGR-18.6%

GINKGO BIOWORKS HLDGS WTS held $84.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

64M

YoY+14.9%

QoQ+3.3%

GINKGO BIOWORKS HLDGS WTS had 64M shares outstanding in Q2 2026. This represents an increase of 14.9% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

91.5%

YoY+5.2pp

QoQ+7.4pp

GINKGO BIOWORKS HLDGS WTS's gross margin was 91.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.4 percentage points.

Return on Equity

-11.1%

YoY-1.3pp

QoQ+7.5pp

5Y change+1067.7pp

GINKGO BIOWORKS HLDGS WTS's ROE was -11.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.5 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$46.2M

YoY-13.4%

QoQ-7.4%

5Y CAGR-2.3%

GINKGO BIOWORKS HLDGS WTS invested $46.2M in research and development in Q2 2026. This represents a decrease of 13.4% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.

Capital Expenditures

$2.6M

YoY+6792.1%

QoQ+35.5%

5Y CAGR-35.8%

GINKGO BIOWORKS HLDGS WTS invested $2.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 6792.1% from the same quarter a year earlier. Against the prior quarter it is up 35.5%.

Share Buybacks

Not reported for Q2 2026.

DNABW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DNABW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	$132.4M	$170.2M-25.1%	$227.0M-9.7%	$251.5M-47.4%	$477.7M+52.2%	$313.8M+309.4%	$76.7M+41.5%	$54.2M
R&D Expenses	$215.6M	$243.8M-42.5%	$424.1M-27.0%	$580.6M-44.8%	$1.1B-8.4%	$1.1B+619.6%	$159.8M+65.9%	$96.3M
SG&A Expenses	$177.2M	$183.3M-25.5%	$246.2M-36.1%	$385.0M-73.1%	$1.4B+65.7%	$863.0M+2152.8%	$38.3M+29.9%	$29.5M
Operating Income	-$306.1M	-$315.3M+43.7%	-$559.8M+35.2%	-$864.4M+60.9%	-$2.2B-20.8%	-$1.8B-1234.4%	-$137.0M-91.4%	-$71.6M
EBITDA	N/A	-$256.3M+48.4%	-$496.7M+37.4%	-$793.9M+63.4%	-$2.2B-20.4%	-$1.8B-1361.0%	-$123.2M-102.4%	-$60.8M
Interest Expense	-$5.3M	$0-100.0%	$94K+1.1%	$93K-12.3%	$106K-95.5%	$2.4M-0.5%	$2.4M-1.5%	$2.4M
Income Tax	-$594K	-$837K-74.7%	-$479K-574.6%	-$71K+99.5%	-$15.0M-915.3%	-$1.5M-178.3%	$1.9M+8486.4%	$22K
Net Income	$21.6M	-$313K+42.8%	-$547K+38.7%	-$893K+57.6%	-$2.1M-15.0%	-$1.8M+98.6%	-$126.6M-6.1%	-$119.3M
EPS (Basic)	N/A	-$5.64-53614.3%	-$0.01+42.9%	-$0.02+100.0%	-$50.15-3614.8%	-$1.35-1250.0%	-$0.100.0%	-$0.10
EPS (Diluted)	—	-$5.64	-$0.01+42.9%	-$0.02	-$0.05	-$1.39	-$0.100.0%	-$0.10
Diluted Shares (Avg)	N/A	55M	52M+6.8%	49M	42M	1.36B	1.27B+10.9%	1.15B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$20.2M-48.5%	$19.5M-49.1%	$54.0M+23.1%	$38.8M-56.4%	$39.1M-30.4%	$38.2M+0.8%	$43.8M+26.2%	$89.0M+60.6%
Cost of Revenue	$1.7M-68.0%	$3.1M-24.3%	N/A	N/A	$5.4M	$4.1M	N/A	N/A
Gross Profit	$18.4M-45.4%	$16.4M-52.0%	N/A	N/A	$33.8M	$34.1M	N/A	N/A
R&D Expenses	$46.2M-13.4%	$49.9M-29.6%	$50.1M-34.4%	$69.4M-9.9%	$53.4M-60.2%	$70.9M-48.0%	$76.4M-34.7%	$77.0M-50.8%
SG&A Expenses	$30.8M-12.0%	$37.8M-4.8%	$63.6M+11.1%	$45.0M-14.0%	$35.0M-47.2%	$39.7M-43.5%	$57.3M-35.8%	$52.3M-36.3%
Operating Income	-$58.5M-0.7%	-$71.4M+11.9%	-$86.1M+16.9%	-$90.0M-63.1%	-$58.2M+73.9%	-$81.0M+54.5%	-$103.6M+41.8%	-$55.2M+80.7%
EBITDA	-$46.2M-7.7%	-$58.6M+11.5%	-$72.5M+17.6%	-$74.8M-96.6%	-$42.9M+79.1%	-$66.2M+59.9%	-$88.0M+46.8%	-$38.0M+85.7%
Interest Expense	$3.2M-46.9%	$3.6M-40.9%	-$17.9M-325.3%	$5.7M+162.1%	$6.1M+159.0%	$6.1M-48.1%	$7.9M-46.7%	-$9.3M+38.4%
Income Tax	$128K+145.2%	-$80K-190.9%	-$643K-97.8%	$1K+100.3%	-$283K-248.9%	$88K+183.9%	-$325K-64.1%	-$375K-1604.5%
Net Income	-$46.7M+22.5%	-$82.6M+9.2%	$231.7M-47.2%	-$80.8M-43.2%	-$60.3M+72.2%	-$91.0M+45.2%	$438.9M-35.5%	-$56.4M+81.4%
EPS (Basic)	-$0.75+31.8%	-$1.39+17.3%	-$1.42+27.6%	-$1.45-34.3%	-$1.10+74.0%	-$1.68+49.2%	-$1.96+54.2%	-$1.08+82.6%
EPS (Diluted)	N/A	N/A	-$1.42+27.6%	-$1.45-34.3%	-$1.10	-$1.68	-$1.96+54.2%	-$1.08
Diluted Shares (Avg)	N/A	N/A	N/A	56M+6.5%	55M	54M	N/A	52M

DNABW Balance Sheet

DNABW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$1.1B-18.7%	$1.4B-17.3%	$1.7B-34.4%	$2.5B+22.6%	$2.1B+206.7%	$675.2M-3.2%	$697.3M
Current Assets	$471.8M-21.7%	$602.7M-39.8%	$1.0B-30.9%	$1.5B-15.8%	$1.7B+304.0%	$426.5M-16.7%	$511.9M
Cash & Equivalents	$167.2M-70.2%	$561.6M-40.5%	$944.1M-28.3%	$1.3B-15.1%	$1.6B+307.0%	$380.8M-23.1%	$495.3M
Short-Term Investments	$255.4M	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	$46K-98.9%	$4.4M+29.8%	$3.4M+22.9%	$2.7M	$0
Accounts Receivable	$24.0M+9.9%	$21.9M+27.4%	$17.2M-78.8%	$80.9M-38.5%	$131.5M+688.0%	$16.7M+382.3%	$3.5M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	$0-100.0%	$49.2M-18.2%	$60.2M+182.5%	$21.3M+1047.7%	$1.9M0.0%	$1.9M
Total Liabilities	$611.1M-7.6%	$661.4M+16.4%	$568.2M-29.2%	$803.0M+59.5%	$503.6M+145.5%	$205.1M+4.9%	$195.5M
Current Liabilities	$96.0M-10.5%	$107.3M-34.5%	$163.9M-5.3%	$173.0M+28.3%	$134.8M+84.0%	$73.2M+82.7%	$40.1M
Non-Current Liabilities	$515.1M-7.0%	$554.1M+37.0%	$404.3M-35.8%	$630.1M+70.8%	$368.9M+179.7%	$131.9M-15.1%	$155.4M
Total Equity	$508.6M-29.0%	$716.1M-34.7%	$1.1B-36.8%	$1.7B+15.3%	$1.5B+226.3%	$461.4M-6.4%	$493.1M
Retained Earnings	-$6.2B-5.4%	-$5.8B-10.3%	-$5.3B-20.3%	-$4.4B-91.4%	-$2.3B-391.1%	-$467.9M-37.1%	-$341.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$990.0M-19.6%	$1.0B-20.1%	$1.1B-18.7%	$1.2B-19.7%	$1.2B-24.3%	$1.3B-18.2%	$1.4B-17.3%	$1.5B-26.9%
Current Assets	$332.5M-36.4%	$410.0M-27.4%	$471.8M-21.7%	$506.1M-23.6%	$523.0M-33.2%	$564.5M-37.5%	$602.7M-39.8%	$662.5M-42.0%
Cash & Equivalents	$84.5M-58.5%	$143.9M-54.0%	$167.2M-70.2%	$111.1M-82.0%	$203.6M-72.1%	$312.4M-62.8%	$561.6M-40.5%	$616.2M-41.3%
Short-Term Investments	$0-100.0%	$0-100.0%	$255.4M	$384.4M	$355.8M	$12.8M	$0	$0
Accounts Receivable	$13.0M-41.3%	$19.8M-24.6%	$24.0M+9.9%	$21.4M-8.5%	$22.2M+19.2%	$26.3M+8.7%	$21.9M+27.4%	$23.4M-62.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$0-100.0%
Total Liabilities	$569.8M-7.8%	$589.9M-8.7%	$611.1M-7.6%	$629.4M-7.8%	$618.1M-22.0%	$646.0M+8.7%	$661.4M+16.4%	$682.9M-11.7%
Current Liabilities	$72.7M-24.8%	$79.6M-31.2%	$96.0M-10.5%	$115.3M+0.7%	$96.7M-41.8%	$115.7M-31.6%	$107.3M-34.5%	$114.4M-32.1%
Non-Current Liabilities	$497.0M-4.7%	$510.3M-3.8%	$515.1M-7.0%	$514.1M-9.6%	$521.3M-16.7%	$530.4M+24.7%	$554.1M+37.0%	$568.5M-6.1%
Total Equity	$420.3M-31.4%	$443.2M-31.6%	$508.6M-29.0%	$559.8M-29.8%	$613.0M-26.4%	$647.4M-34.4%	$716.1M-34.7%	$797.9M-36.3%
Retained Earnings	-$6.3B-4.9%	-$6.2B-5.1%	-$6.2B-5.4%	-$6.1B-5.9%	-$6.0B-5.6%	-$5.9B-8.7%	-$5.8B-10.3%	-$5.7B-12.8%

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

DNABW Cash Flow Statement

DNABW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	-$170.2M	-$171.1M+46.5%	-$319.6M-8.2%	-$295.5M-17.2%	-$252.2M+0.6%	-$253.8M-86.9%	-$135.8M-204.1%	-$44.7M
Depreciation & Amortization	N/A	$59.0M-6.4%	$63.0M-10.6%	$70.5M+65.7%	$42.6M+46.3%	$29.1M+109.7%	$13.9M+28.9%	$10.8M
Stock-Based Compensation	N/A	$81.5M-27.4%	$112.3M-51.1%	$229.9M-88.1%	$1.9B+20.2%	$1.6B+337299.2%	$476K-38.3%	$771K
Capital Expenditures	$4.6M	$7.7M-87.7%	$62.5M+53.3%	$40.8M-21.9%	$52.3M-7.5%	$56.5M-2.2%	$57.8M+160.2%	$22.2M
Free Cash Flow	-$174.8M	-$178.7M+53.2%	-$382.1M-13.6%	-$336.3M-10.5%	-$304.5M+1.9%	-$310.3M-60.3%	-$193.7M-189.5%	-$66.9M
Investing Cash Flow	$56.5M	-$240.3M-286.1%	-$62.2M+22.9%	-$80.7M-19.7%	-$67.4M+8.0%	-$73.3M-9.1%	-$67.1M+10.0%	-$74.6M
Financing Cash Flow	$34.5M	$17.8M+1122.1%	-$1.7M+45.9%	-$3.2M-103.4%	$95.3M-93.8%	$1.5B+1598.6%	$90.3M-78.0%	$410.4M
Dividends Paid	N/A	$0	$0	$0	$0	$0	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0-100.0%	$25.0M	$0-100.0%	$408K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$44.3M-10.0%	-$46.7M+9.4%	-$47.7M-12.4%	-$31.6M+69.5%	-$40.3M+52.3%	-$51.5M+42.3%	-$42.4M+26.6%	-$103.5M-40.7%
Depreciation & Amortization	$12.3M-19.2%	$12.8M-13.6%	$13.7M-12.7%	$15.3M-11.1%	$15.2M-12.0%	$14.8M+15.2%	$15.7M+21.9%	$17.2M-18.5%
Stock-Based Compensation	$7.6M-59.6%	$15.9M-8.8%	N/A	$17.8M+28.8%	$18.8M-49.4%	$17.4M-57.4%	N/A	$13.9M-73.6%
Capital Expenditures	$2.6M+6792.1%	$1.9M-74.6%	$5K-100.0%	$0-100.0%	$38K-99.9%	$7.6M+13.6%	$13.7M+297.9%	$15.1M+244.4%
Free Cash Flow	-$46.9M-16.4%	-$48.6M+17.8%	-$47.7M+15.1%	-$31.6M+73.3%	-$40.3M+63.8%	-$59.1M+38.4%	-$56.1M+8.4%	-$118.6M-52.2%
Investing Cash Flow	$11.1M+117.4%	$23.1M+111.6%	$95.1M+826.8%	-$72.8M-613.9%	-$63.9M-138.0%	-$198.7M-1540.7%	-$13.1M+72.0%	-$10.2M-201.7%
Financing Cash Flow	$16.5M+16925.5%	-$19K+90.8%	$8.1M+4110.8%	$9.9M+2237.2%	-$98K+56.6%	-$207K+75.5%	-$203K+67.9%	-$465K-47.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

DNABW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DNABW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Margin	-185.3%	-246.5%	-343.8%	-462.4%	-582.6%	-178.8%	-132.1%
Net Margin	-0.2%+0.1pp	-0.2%+0.1pp	-0.4%+0.1pp	-0.4%+0.1pp	-0.6%	-165.2%	-220.2%
Return on Equity	-0.1%0.0pp	-0.1%0.0pp	-0.1%0.0pp	-0.1%0.0pp	-0.1%+27.3pp	-27.4%-3.2pp	-24.2%
Return on Assets	0.0%0.0pp	0.0%0.0pp	-0.1%0.0pp	-0.1%0.0pp	-0.1%+18.7pp	-18.8%-1.6pp	-17.1%
Current Ratio	4.92-0.7x	5.62-0.5x	6.11-2.3x	8.38-4.4x	12.79+7.0x	5.83-6.9x	12.77
Debt-to-Equity	1.20+0.3x	0.92+0.4x	0.52+0.1x	0.46+0.1x	0.33-0.1x	0.440.0x	0.40
Asset Turnover	0.150.0x	0.160.0x	0.150.0x	0.190.0x	0.150.0x	0.110.0x	0.08
FCF Margin	-105.0%	-168.3%	-133.7%	-63.7%+35.2pp	-98.9%	-252.6%	-123.4%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	91.5%+5.2pp	84.1%-5.2pp	N/A	N/A	86.3%	89.3%	N/A	N/A
Operating Margin	-290.5%	-366.5%	-159.6%	-231.8%	-148.6%	-211.8%	-236.3%	-62.0%
Net Margin	-231.7%	-424.1%	429.4%	-207.9%	-154.1%	-237.9%	1001.1%	-63.3%
Return on Equity	-11.1%-1.3pp	-18.6%-4.6pp	45.6%-15.7pp	-14.4%-7.4pp	-9.8%+16.2pp	-14.1%+2.8pp	61.3%-0.7pp	-7.1%+17.1pp
Return on Assets	-4.7%+0.2pp	-8.0%-1.0pp	20.7%-11.2pp	-6.8%-3.0pp	-4.9%+8.5pp	-7.0%+3.5pp	31.9%-9.0pp	-3.8%+11.1pp
Current Ratio	4.57-0.8x	5.15+0.3x	4.92-0.7x	4.39-1.4x	5.41+0.7x	4.88-0.5x	5.62-0.5x	5.79-1.0x
Debt-to-Equity	1.36+0.3x	1.33+0.3x	1.20+0.3x	1.12+0.3x	1.01+0.1x	1.00+0.4x	0.92+0.4x	0.86+0.2x
Asset Turnover	0.020.0x	0.020.0x	0.050.0x	0.030.0x	0.030.0x	0.030.0x	0.030.0x	0.060.0x
FCF Margin	-232.6%	-249.7%	-88.4%	-81.4%	-103.0%	-154.7%	-128.1%	-133.2%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Where GINKGO BIOWORKS HLDGS WTS Ranks

Frequently Asked Questions

What is GINKGO BIOWORKS HLDGS WTS's annual revenue?

GINKGO BIOWORKS HLDGS WTS (DNABW) reported $170.2M in total revenue for fiscal year 2025. This represents a -25.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is GINKGO BIOWORKS HLDGS WTS's revenue growing?

GINKGO BIOWORKS HLDGS WTS (DNABW) revenue declined by 25.1% year-over-year, from $227.0M to $170.2M in fiscal year 2025.

Is GINKGO BIOWORKS HLDGS WTS profitable?

No, GINKGO BIOWORKS HLDGS WTS (DNABW) reported a net income of -$313K in fiscal year 2025, with a net profit margin of -0.2%.

What is GINKGO BIOWORKS HLDGS WTS's EBITDA?

GINKGO BIOWORKS HLDGS WTS (DNABW) had EBITDA of -$256.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is GINKGO BIOWORKS HLDGS WTS's net profit margin?

GINKGO BIOWORKS HLDGS WTS (DNABW) had a net profit margin of -0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is GINKGO BIOWORKS HLDGS WTS's return on equity (ROE)?

GINKGO BIOWORKS HLDGS WTS (DNABW) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is GINKGO BIOWORKS HLDGS WTS's free cash flow?

GINKGO BIOWORKS HLDGS WTS (DNABW) recorded an outflow of $178.7M in free cash flow during fiscal year 2025. This represents a 53.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is GINKGO BIOWORKS HLDGS WTS's operating cash flow?

GINKGO BIOWORKS HLDGS WTS (DNABW) recorded an outflow of $171.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are GINKGO BIOWORKS HLDGS WTS's total assets?

GINKGO BIOWORKS HLDGS WTS (DNABW) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are GINKGO BIOWORKS HLDGS WTS's capital expenditures?

GINKGO BIOWORKS HLDGS WTS (DNABW) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does GINKGO BIOWORKS HLDGS WTS spend on research and development?

GINKGO BIOWORKS HLDGS WTS (DNABW) invested $243.8M in research and development during fiscal year 2025.

How many shares does GINKGO BIOWORKS HLDGS WTS have outstanding?

GINKGO BIOWORKS HLDGS WTS (DNABW) had 58M shares outstanding as of fiscal year 2025.

What is GINKGO BIOWORKS HLDGS WTS's current ratio?

GINKGO BIOWORKS HLDGS WTS (DNABW) had a current ratio of 4.92 as of fiscal year 2025, which is generally considered healthy.

What is GINKGO BIOWORKS HLDGS WTS's debt-to-equity ratio?

GINKGO BIOWORKS HLDGS WTS (DNABW) had a debt-to-equity ratio of 1.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is GINKGO BIOWORKS HLDGS WTS's return on assets (ROA)?

GINKGO BIOWORKS HLDGS WTS (DNABW) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is GINKGO BIOWORKS HLDGS WTS's Piotroski F-Score?

GINKGO BIOWORKS HLDGS WTS (DNABW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are GINKGO BIOWORKS HLDGS WTS's earnings high quality?

GINKGO BIOWORKS HLDGS WTS (DNABW) reported a net loss of $313K while operations used $171.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.